David O'Malley, MD, discusses the role of PARP inhibitors in the treatment landscape of ovarian cancer.
David O'Malley, MD, professor in the Department of Obstetrics and Gynecology at The Ohio State University College of Medicine, and director of the Division of Gynecologic Oncology at The Ohio State University Comprehensive Cancer Center–The James, discusses the role of PARP inhibitors in the treatment landscape of ovarian cancer.
We now know there is a group of patients who will benefit remarkably from the use of PARP inhibitors, and that includes patients who have either a BRCA1 or BRCA2 mutation, says O’Malley. Whenever a survival advantage is seen, we know it is going to be beneficial. It is clear now that this group of patients with BRCA1/2-mutant ovarian cancer will benefit from PARP inhibitors, and they should receive these therapies earlier on.
There are 3 PARP inhibitors now available in the treatment landscape for ovarian cancer, with the most recent approval of niraparib (Zejula) in the frontline setting for adult patients who are in a complete or partial response to first-line platinum-based chemotherapy. According to O’Malley, PARP inhibitors should be given in the frontline setting for patients harboring a BRCA1/2 mutation, but if they do not receive it in their first-line of therapy and receive a platinum instead, they should be receiving a PARP inhibitor in the platinum-sensitive, recurrent setting.
Darolutamide Becomes Routine Doublet and Triplet Option in Hormone-Sensitive Prostate Cancer
May 6th 2024Darolutamide has been adopted routinely in clinical practice as a component of both doublet and triplet regimens for the treatment of patients with metastatic hormone-sensitive prostate cancer.
Read More
Responders to UGN-101 Have Positive RFS in Upper Tract Urothelial Cancer
May 5th 2024In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.
Read More
UGN-101 Shows Promise for Upper Tract Urothelial Cancer Durability
May 5th 2024Maintenance UGN-101 therapy demonstrated good durability of response in initial responders with low-grade upper tract urothelial cancer, as evidenced by a low rate of disease progression in a multicenter, longitudinal follow-up study.
Read More